Drug Trial Radar · NCT06918808
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
May 19, 2025
Primary completion
Jul 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Direct Biologics, LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.
Conditions
- Perianal Fistula Due to Crohn's Disease
Interventions
DB-3QBiological
DB-3Q (IMP) is the frozen liquid formulation of acellular secretome proteins and extracellular vesicles isolated from human bmMSC and processed under current Good Manufacturing Process standards.
PlaceboBiological
0.9% NaCl
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined RemissionTime frame: 24 Weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Direct Biologics Investigational Site
Aurora, Colorado · Recruiting
Direct Biologics Investigational Site
St Louis, Missouri · Recruiting
Columbia University Irving Medical Center/NYPH
New York, New York · Recruiting
Direct Biologics Investigational Site
Philadelphia, Pennsylvania · Recruiting
Direct Biologics Investigational Site
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.